Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $349.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by UBS Group from $331.00 to $349.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on ALNY. Scotiabank upped their price objective on […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by UBS Group from $331.00 to $349.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on ALNY. Scotiabank upped their price objective on […]
